Prior SARS-CoV-2 infection enhances Johnson and Johnson Ad26.COV2.S vaccine immunogenicity

By | July 30, 2021
A new study reports that the Johnson and Johnson vaccine against COVID-19 shows enhanced efficacy when administered to individuals with pre-existing antibodies.